Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

NCT05641831 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Clonal Cytopenia of Undetermined Significance

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration and Biopsy
DRUG: Canakinumab
PROCEDURE: Chest Radiography
PROCEDURE: Echocardiography
DRUG: Placebo Administration
OTHER: Quality-of-Life Assessment

Sponsor

Uma Borate